Oral Peptides Biotech Pinnacle Medicines Gets $89M From US, China Investors
Pinnacle Medicines, a two‑year‑old biotech focused on oral peptide therapeutics, secured $89 million from a mix of U.S. and Chinese investors. The financing will fund its platform that converts injectable peptides into pill form, building on the recent success of Novo Nordisk’s oral semaglutide (Wegovy). Pinnacle’s pipeline targets obesity, diabetes and several rare metabolic disorders. The raise underscores growing investor confidence in oral peptide technology as a next‑generation drug delivery approach.
Otsuka Pharmaceutical Reports P-III (VISIONARY) Trial Data on Voyxact for IgA Nephropathy (IgAN)
Otsuka Pharmaceutical presented Phase III VISIONARY trial data for Voyxact (sibeprenlimab‑szsi) in IgA nephropathy patients at risk of progression. At 48 weeks, 82.5% of patients receiving 400 mg subcutaneous Voyxact achieved negative microscopic hematuria versus 52.6% on placebo, with median time to...
Biogen and Alteogen Partner for ALT-B4 to Advance Subcutaneous Formulations of Biologics
Biogen has signed an exclusive license with South Korean biotech Alteogen for ALT‑B4, a recombinant hyaluronidase enzyme that facilitates subcutaneous administration of biologics traditionally given intravenously. The agreement provides Alteogen with $20 million upfront, a $10 million payment upon initiation of a...
Probiotics Drink Reduces Loose Stools Tendency in Healthy Adults - Study
A randomized, double‑blind trial in Japan found that a daily 100 ml drink containing 10 billion CFU of Lactiplantibacillus plantarum 299v reduced bowel‑movement frequency and days with defecation in healthy adults prone to loose stools. After eight weeks, the probiotic group averaged 6.7...
ELMED Life Sciences Raises $2.7 Mn in Series A From NABVENTURES
ELMED Life Sciences secured a $2.7 million Series A round led by NABVENTURES' AgriSURE Fund. The capital will fund new manufacturing capacity in Hyderabad, R&D acceleration, and broader distribution across Indian tier‑2/3 regions and overseas markets. ELMED develops probiotic and microbiome‑based products...
Beyond the Cornfields, Indiana’s Life Sciences Industry Grows Tall
Indiana’s life‑sciences sector is rapidly expanding, now encompassing over 3,300 companies that employ roughly 70,000 workers and generate a $102 billion economic impact. Flagship firms such as Eli Lilly are driving major investments, including a $13 billion Medicine Foundry slated to create 400...
China’s Jiangsu Aidea Eyes Hong Kong Listing as Gateway to US and European Aids Markets
Jiangsu Aidea Pharmaceutical, a Shanghai‑Star Market listed firm specializing in HIV/AIDS therapies, is preparing a Hong Kong IPO to fund its expansion into the United States and Europe. The company projects the global AIDS‑treatment market to exceed $1.45 billion by 2027...
Hong Kong: Research and Tech Driving Life and Health Innovation
Hong Kong Science and Technology Parks Corporation convened leading life‑science firms, investors and partners at its CTC Marketplace to showcase the city’s emerging health‑tech ecosystem. The event highlighted Hong Kong’s strengths in translational research, clinical‑trial capacity and AI‑driven drug discovery,...
MHRA’s Tallon on the Tall Order of Boosting the U.K. as a Destination for Clinical Trials
Lawrence Tallon, the MHRA chief, is set to oversee the launch of the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 on April 28, 2026. The amendment represents the most extensive overhaul of U.K. clinical‑trial rules in two decades, targeting faster approval,...
Regulatory Education for Industry (REdI) Annual Conference 2026: Innovative Regulatory Strategies to Advance Medical Products - 05/19/2026
The FDA’s Regulatory Education for Industry (REdI) Annual Conference will take place May 19‑20, 2026, offering both virtual and in‑person sessions at the White Oak Campus in Maryland. The two‑day program features three dedicated tracks—drugs, devices, and biologics—allowing participants to...
FDA Approves Avlayah as Treatment of Hunter Syndrome
Denali Therapeutics received accelerated FDA approval for Avlayon (tividenofusp alfa‑eknm), the first enzyme replacement therapy designed to cross the blood‑brain barrier for Hunter syndrome. The approval is based on a phase 1/2 trial of 47 boys up to 18 years, showing...
FY 2025 GDUFA Science and Research Report
The FDA’s Center for Drug Evaluation and Research released its FY 2025 GDUFA Science & Research Report, detailing more than 50 funded projects across eight priority scientific initiatives. The program targets bioequivalence, manufacturing standards, and advanced analytical methods to streamline abbreviated...
Patent Certifications and Suitability Petitions
Under the Hatch‑Waxman law, generic manufacturers must file a Paragraph IV certification asserting that a listed patent is invalid, unenforceable, or not infringed to obtain FDA approval. The first substantially complete ANDA with such a certification secures a 180‑day exclusivity period,...
This Cutting-Edge Treatment Hit the Rewind Button On Aging, Scientists Say
Researchers at Longeveron reported that a single infusion of laromestrocel, a mesenchymal stem‑cell therapy derived from donors aged 14‑18, significantly boosted mobility in frail seniors. In a double‑blind trial of about 150 participants aged 70‑85, the highest dose (200 million cells)...
IP Considerations Following FDA Announcement on Flexibility for Cell and Gene Therapies
The FDA announced new guidance that expands flexibility in chemistry, manufacturing, and controls (CMC) for cell and gene therapies (CGTs) across their development lifecycle. Sponsors can now defer full cGMP compliance until later trial phases and make iterative manufacturing changes...
FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
The FDA granted accelerated approval to Avlayah (tividenofusp alfa‑eknm), a weekly IV infusion, for treating neurologic manifestations of Hunter syndrome in pediatric patients weighing at least 5 kg. The approval is based on a phase 1/2 trial that demonstrated a 91% average...
Leveraging the Full Potential of Regenerative Medicine Requires a Proactive Approach
Regenerative medicine promises to shift healthcare from a reactive model to proactive disease modification by targeting early biological drivers of chronic degeneration. Cell‑based therapies such as mesenchymal stromal/stem cells (MSCs) can modulate inflammation, immune signaling, and tissue repair, showing benefits...
Parasites Prompt Gut-Brain Communication to Trigger Appetite Loss
UCSF researchers have mapped a gut‑brain signaling cascade that explains why parasitic worm infections cause loss of appetite. They discovered that tuft cells detect parasite‑derived succinate and release acetylcholine, which prompts nearby enterochromaffin cells to secrete serotonin. The serotonin then...
GlycoNet – Sugar-Based Vaccine Against Bacterial Diarrhea Shows Promise in Phase 1 Trial
Researchers at the University of Guelph announced that their sugar‑based vaccine candidate against Campylobacter jejuni demonstrated safety and immunogenicity in a small Phase 1 human trial. Participants experienced only mild side effects, and the formulation generated measurable antibody responses even at...
Anavex Sinks After Pulling Alzheimer's Filing in EU
Anavex Life Sciences withdrew its European marketing authorisation application for blarcamesine, an add‑on therapy for early‑stage Alzheimer’s, after the EMA’s CHMP signaled a likely negative opinion. The committee criticized the trial’s efficacy data, methodological flaws, and safety reporting, including concerns...
Drug Quality Sampling and Testing Programs
The FDA’s Center for Drug Evaluation and Research (CDER) released its FY 25 Drug Quality Sampling and Testing results, showing that the vast majority of tested pharmaceuticals met USP specifications. The program uses a risk‑based, data‑driven approach introduced in 2018 to...
New Drug Candidates Debut in Atlanta
At the ACS Spring 2026 meeting in Atlanta, the Medicinal Chemistry division unveiled six new drug candidates transitioning from discovery to clinical testing. The molecules, presented by researchers from Biohaven, Bristol Myers Squibb, Regor Therapeutics, Olema Oncology, FoRx Therapeutics, and Iambic Therapeutics,...
How Seaport Is Hedging Against Failure in Phase 2b Depression Study
Seaport Therapeutics is embedding a fail‑safe mechanism into its Phase 2b trial of SPT‑300, an experimental therapy for major depressive disorder. The study will enroll roughly 300 patients at multiple U.S. sites and uses an adaptive design that can halt...
FDA Approves Relacorilant with Nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
The FDA has approved relacorilant (Lifyorli), a glucocorticoid‑receptor antagonist, in combination with nab‑paclitaxel for adults with platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received up to three prior regimens, including bevacizumab. The approval is based on...
Hemodynamic and Biochemical Effects of Intravenous versus Oral Fluids in Healthy Volunteers – A Protocol for a Randomized Crossover Trial
A Phase 1 randomized crossover trial will compare the hemodynamic impact of 1 liter oral tap water versus 1 liter intravenous Ringer’s lactate in 20 healthy volunteers. The primary endpoint is the change in mean arterial pressure 30 minutes after fluid administration, with secondary...
The Brain's Cleaning System Can Be Boosted to Rid Alzheimer's Proteins
Researchers identified a drug combination that enhances the brain's glymphatic system, improving clearance of Alzheimer‑related proteins. The regimen pairs a widely used sedative with a medication that prevents dangerously low blood pressure, showing safe and effective removal of amyloid and...
STAT+: FDA Approves Denali Therapeutics Drug for Hunter Syndrome
On March 27, 2026, the U.S. Food and Drug Administration granted approval to Denali Therapeutics’ drug Avlayah for the treatment of Hunter syndrome, a rare lysosomal storage disorder. The decision arrives amid a recent wave of stricter FDA scrutiny of...
Scout-Triggered Proteomics Sharpens HCP Control
Host-cell proteins (HCPs) remain a persistent impurity risk in biomanufacturing, with regulators demanding levels below 100 ppm in final drug products. Traditional ELISAs measure total HCPs but cannot identify individual proteins, while conventional multiple reaction monitoring (MRM) suffers from retention‑time shifts...
How Inflammation May Prime the Gut for Cancer
Researchers at the Broad Institute and Harvard uncovered that chronic intestinal inflammation imprints lasting epigenetic scars on gut cells, even after tissue appears healed. In mouse models, these epigenetic memories persist through many cell divisions and, when paired with a...
Improving Early Detection and Treatment of Liver Cancer
Early-stage liver cancer survival hinges on timely diagnosis, yet ultrasound and AFP tests miss many cases. Helio Genomics has introduced the HelioLiver blood test, a multi‑analyte cfDNA and protein assay that flags tumor‑associated epigenetic signals earlier than imaging. A new...
Beam Looks to Accelerated Approval for AATD Base Editing After Promising Update
Beam Therapeutics announced encouraging Phase 1/2 data for its base‑editing therapy targeting alpha‑1 antitrypsin deficiency (AATD). The trial demonstrated a 30% reduction in the disease‑causing SERPINA1 mutation and a 45% rise in functional protein levels, while confirming a clean safety profile....
Guidance Recap Podcast | Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products
The FDA released a draft guidance on using Bayesian methodology in clinical trials, outlining how sponsors should incorporate prior data, define success criteria, and document analyses. It emphasizes systematic prior construction, transparent operating characteristics, and extensive simulation documentation. The guidance...
Guidance Snapshot Pilot
The FDA has launched a Guidance Snapshot Pilot that distills complex guidance documents into visual, plain‑language one‑page snapshots complemented by podcasts, timelines, and social‑media links. The pilot targets cross‑cutting topics such as Bayesian trial methodology, decentralized clinical elements, and neonatal...
Boehringer Ingelheim Plans for Dealmaking and R&D Spending Amid US Price Pressure
Boehringer Ingelheim announced it will maintain its high‑level R&D spending while exploring dealmaking opportunities in China to counteract mounting U.S. drug‑price pressure. The company is prioritising an obesity‑focused pipeline, betting on the fast‑growing weight‑loss market to sustain revenue. By keeping...
Ozempic Pill Improves Multiple Cardiometabolic Risk Factors
A post‑hoc analysis of the SOUL trial shows that once‑daily oral semaglutide (Ozempic pill) significantly improves several cardiometabolic risk factors in adults with type 2 diabetes at high risk for atherosclerotic cardiovascular disease. Compared with placebo, participants experienced a 3.2 mm Hg greater...
Rentschler Highlights Milford Site Progress and Growth
Rentsc hler Biopharma announced that its Milford, Massachusetts CDMO site has entered a new growth phase, adding a 22,000‑square‑foot cleanroom and four 2,000‑liter single‑use bioreactors. The expansion, the largest in the company’s 150‑year history, brings the U.S. facility to the...
Novo Reports More Triple-G Data From China; Grifols Plots IPO for Biopharma Unit
Novo Nordisk announced that its triple‑agonist candidate UBT251 achieved a mean HbA1c reduction of up to 2.16% after 24 weeks in a phase‑2 study of Chinese patients with type‑2 diabetes. The trial, involving roughly 200 participants, underscores the drug’s potential...
STAT+: Sarepta Therapeutics Shares Rise on Early Promise for Rare Disease Drugs
Sarepta Therapeutics reported that early‑stage trials of two experimental drugs, SRP‑1001 and SRP‑1003, demonstrated safety and signs of efficacy for rare muscle‑wasting disorders. The data sparked a more than 20% surge in the company’s stock during early trading. The results...
UCB Investing $2B To Build Manufacturing Facility in Georgia
UCB announced a $2 billion investment to build a 460,000‑square‑foot biologics manufacturing plant in Gwinnett County, Georgia, its first U.S. production site. The facility will create about 330 permanent jobs and over 1,000 construction positions, leveraging AI, robotics and automation. Georgia...
Xaira’s First Virtual Cell Model Is Largest To-Date, Toward Complex Biology
Xaira Therapeutics unveiled X-Cell, a 4.9‑billion‑parameter virtual cell model that predicts transcriptome‑level responses to genetic perturbations. The model leverages the company’s 25.6 million‑cell X‑Atlas/Pisces CRISPRi Perturb‑seq dataset and demonstrates zero‑shot performance on unseen T‑cell and iPSC contexts. X-Cell uses a diffusion...
GSK’s Two-Speed Strategy: Broad Sourcing and Selective Bets
GSK has accelerated its pipeline build‑out by pairing broad early‑stage partnerships with selective, later‑stage acquisitions such as the up‑to‑$950 million purchase of 35Pharma’s pulmonary‑hypertension candidate HS235. After spinning off Haleon, the company now leans on specialty medicines—accounting for over 40% of...
Why Maze Therapeutics Plunged 20%-Plus Despite 'Overwhelming Positive' Data
Maze Therapeutics reported Phase 2 results for its kidney drug MZE829, showing a 35.6% average reduction in proteinuria after 12 weeks and a 61.8% drop in the FSGS subgroup. The data were hailed as "overwhelmingly positive" but the stock fell more...
New Treatments Target Faulty Genetic Heart Signals
A new DNA‑methylation (episignature) test can differentiate harmful from benign NOTCH1 variants in congenital heart disease, giving families definitive genetic answers. The assay scans over 740,000 genomic sites to identify a characteristic methylation pattern linked to disease‑causing mutations. Positive results...
Microneedle Vaccine Patch Company Raises $50M for Pivot to GLP-1 Delivery
Terrestrial Bio, the microneedle vaccine patch pioneer originally founded as Vaxess Technologies, announced a $50 million Series B financing round to shift its focus from vaccines to GLP‑1 peptide delivery. The capital, led by a consortium of biotech investors, will fund clinical...
Study Shows How Lymph Node Architecture Affects Cancer Growth
Researchers from EMBL Heidelberg and partner institutions have created the first detailed map of immune and stromal cell organization within human lymph nodes, revealing how this architecture deteriorates in lymphomas. They discovered an inflammatory vicious cycle where T‑cell interferon signals...
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq
RA Capital Management has filed a prospectus for a new SPAC, Research Alliance III, with up to $57.5 million of capital. The blank‑check vehicle is openly scouting life‑science startups, emphasizing Chinese drug developers as potential targets. While the SPAC has not yet...
Building the Path to 3D-Printed Organs, Cellbricks Raises €10M for Biofabricated Tissue Implants
Berlin‑based Cellbricks Therapeutics secured €10 million (≈$11 million) in funding, including a €7 million seed round and over €3 million of non‑dilutive capital, to advance its light‑based biofabrication platform. The company aims to commercialise vascularised human tissue implants for complex wound healing and breast...
Genes From Giant Viruses Help Polar Algae Survive Frigid Waters and Harsh Sunlight
Researchers have found that giant viruses contribute roughly five percent of the genome in polar algae, the highest proportion recorded for any host. In the unicellular green algae Chlamydomonas, more than 400 virus‑derived regions encode over 25,000 genes, including ice‑binding...
